Myelodysplastic syndromes - azacitidine: final appraisal determination 2

After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on azacitidine for the treatment of myelodyplastic syndrome, chronic myelomonocytic leukaemia, and acute myeloid leukaemiaand submitted it to the Institute.

The FAD has been sent to the formal consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England and Wales.

Please note that the appeal period for this appraisal will close at 5pm on 3 March 2011.

This page was last updated: 17 February 2011